News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold

October 8, 2018

Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

August 30, 2018

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

August 27, 2018

Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

August 8, 2018

Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

August 3, 2018

Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

June 15, 2018

Affimed to Present at the Jefferies Global Healthcare Conference

May 30, 2018

Affimed Announces Annual General Meeting of Shareholders

May 18, 2018

Affimed Reports Financial Results for First Quarter 2018

May 15, 2018

Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call

May 8, 2018

Events

All

Scientific

Investors

02Nov

PEGS Europe

November 2 - 4, 2021 (Barcelona, Spain)

Webcasts
More events